Detalhe da pesquisa
1.
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Clin Infect Dis
; 73(7): e1507-e1517, 2021 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32897367
2.
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.
Antimicrob Agents Chemother
; 64(6)2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32179519
3.
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.
Antimicrob Agents Chemother
; 63(1)2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30373807
4.
Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia.
Antibiotics (Basel)
; 12(8)2023 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627757
5.
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.
Diagn Microbiol Infect Dis
; 103(3): 115713, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35598410
6.
A novel C-terminal mutation resulting in constitutive activation of the Listeria monocytogenes central virulence regulatory factor PrfA.
Microbiology (Reading)
; 157(Pt 11): 3138-3149, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21835879
7.
A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Pediatr Infect Dis J
; 40(6): e222-e229, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33480665
8.
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
Diagn Microbiol Infect Dis
; 94(3): 304-313, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808530
9.
Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015.
Infect Drug Resist
; 11: 1309-1320, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30214251
10.
Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
Diagn Microbiol Infect Dis
; 88(2): 184-187, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28377166
11.
Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines.
Diagn Microbiol Infect Dis
; 89(1): 83-85, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28669676
12.
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.
Microb Drug Resist
; 23(6): 718-726, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28727951
13.
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.
Diagn Microbiol Infect Dis
; 87(3): 268-271, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28038840
14.
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
J Glob Antimicrob Resist
; 10: 271-276, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28735051
15.
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.
Infect Dis Ther
; 5(4): 535-544, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718118
16.
Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014).
Diagn Microbiol Infect Dis
; 86(3): 300-302, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27608537
17.
A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.
Future Microbiol
; 10(8): 1325-38, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26083676
18.
Probing the role of protein surface charge in the activation of PrfA, the central regulator of Listeria monocytogenes pathogenesis.
PLoS One
; 6(8): e23502, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21858145